Lucira Health, Inc.
DelistedCIK 1652724fmd_0E2M4RK0RJVWK1H7VEN6TP7S68Manufacturing · In Vitro & In Vivo Diagnostic SubstancesTemplate: Standard
Coverage: Jan 01, 2020 to Sep 30, 2022, 11 periods
| Line item | FY2020 | FY2021 |
|---|---|---|
| Total revenues | 0 | 93 |
| Cost of revenue | 2 | 81 |
| Gross profit | (2) | 10 |
| Research and development | 25 | 40 |
| Selling, general and administrative | 6 | 36 |
| Total operating expenses | 30 | 75 |
| Operating income | (32) | (65) |
| Interest expense | 0 | 0 |
| Interest and investment income | – | 0 |
| Other non-operating income (expense) | (5) | 0 |
| Income before taxes | (37) | (65) |
| Income tax expense | – | 0 |
| Net income from continuing operations | – | (65) |
| Net income | (37) | (65) |